ISRG Deep Dive: A franchise worth owning at a price that asks for more than we can find

At the 11-02-2026 close of $436.87 the shares carried a market value of $151.4 billion and traded at 55.5 times last year's reported earnings per share. We value the company at $118.22 per share on a downside path, $193.46 on our reference path and $268.49 on an upside path, which is 27.1%, 44.3% and 61.5% of that close. Those are conditional values at 11-02-2026, not forecasts of where the stock goes, and we attach no probabilities to them. What matters is that the price sits above all three, and that no single judgment we could defend closes the gap. At the 11-02-2026 close, a discount rate of 6.48% would do it, against the 9.91% we use, and so would da Vinci procedure growth 14.1 points higher in every year from 2027 to 2035, which means 26.1% growth in 2027 and 19.6% in 2035, from a base that grew about 14% in the third quarter. Putting together the favorable end of each of the eight judgments our independent challenge tested gives $358.94 per share, 82.2% of that close. We treat that as a stress rather than a case, and it answers a bounded question, how generous those eight judgments would have to be, because it keeps the announced price cut at our reference setting and leaves the volume response, mix and price erosion where the reference has them. The 11-09-2026 settled close of $460.56 is 5.4% above the valuation-date close and still sits above all three values; the section after this one sets our unchanged values against it. Unless a sentence names another date, "the close" in this report is the 11-02-2026 close of $436.87, the price at which the rating was assessed.

The risk in saying this is not subtle. Intuitive has compounded procedures at mid-teens rates for years, and a forecast that fades growth, as ours does, would have been too cautious about most of the eight years we read. We hold no record of how the shares were valued over that time, so whether models like ours looked too low on it is our judgment and not something we measured. We build that argument out below and we keep it in view. Our Blockhaven Rating, 1 / 5 POOR at the 11-02-2026 close of $436.87, is a statement about the price, and the price is the only thing about this company we find hard to defend. Three things in that sentence are worth keeping apart. Our values are what the model computes the shares to be worth at the 11-02-2026 valuation date, from an explicit forecast to 2035 with a terminal value. The rating weighs the price against those values and the evidence behind them. How the shares perform over the next twelve months is a separate question, and this research does not forecast it: the gap between the close and our values is measured at the valuation date, and how long it would take to close, if it closes at all, is not something we predict.

Two things moved and the valuation did not. The higher price widened the gap on every path: the downside value is now 74.3% below the close instead of 72.9%, the reference 58.0% instead of 55.7%, and the upside 41.7% instead of 38.5%. Put the other way, the 11-09-2026 close is 71.5% above the upside value, 138.1% above the reference and 289.6% above the downside. The path was not smooth. The close reached $482.10 on 11-04-2026, eased to $452.80 by 11-06-2026 and recovered to $460.56 on 11-09-2026 without regaining that level, and we captured no company statement from those days, so we offer no explanation for the move. The yield fell five basis points through 11-06-2026, which works the other way but by little: scaled from the one-point sensitivities in the appendix below, five basis points is worth about $1.28 to $1.80 per share on the reference, against a price that is $23.69 higher than the valuation-date close.

The reverse valuation moves with the price. The table keeps the 11-02-2026 results as the dated original beside the same measures solved again at the 11-09-2026 close, with the rest of the reference held.

At the higher close the reference cash flows equal the price only at a discount rate of 6.35%, which at a beta of 1.0 implies an equity risk premium of 1.44 points, or with da Vinci growth 15.0 points higher in every year from 2027 to 2035, which means 27.0% growth in 2027 and 20.5% in 2035. Both sit further from our assumptions than they did at the 11-02-2026 close, against the 9.91% we use and a base that grew about 14% in the third quarter. The multiples moved the same way, to 58.5 times 2025 earnings per share and a market value of $159.7 billion.

What did not move is the valuation itself. The values in this report are those of 11-02-2026. We have not rolled them forward, recalculated them or changed an assumption, and the discount rate is still 9.91%, built on the 4.91% yield of the valuation date. The relation of the price to the values is the same as at the valuation date: the 11-09-2026 close is above the upside value, so no path crosses it, and the favorable end of each of the eight judgments our independent challenge tested, $358.94, is 77.9% of it, against 82.2% of the valuation-date close, while the adverse stack of $117.67 is 25.5% and the no-growth value of $105.31 is 22.9%. No threshold the rating relies on has been crossed. A 2 / 5 reading would need a close near our upside value, which is now a close 41.7% lower than the 11-09-2026 settled close, and a 3 / 5 reading a close near our reference, 58.0% lower. The list of Intuitive's SEC filings that we hold was retrieved on 11-07-2026 and shows no periodic or event filing after our earlier evidence date, only insider filings; we did not repeat that check for the 11-09-2026 close, so we have no new operating evidence to weigh against the price. The comparison therefore does not change our reading. The Blockhaven Rating stays 1 / 5 POOR at the 11-02-2026 close of $436.87, and a close 5.4% higher would not by itself argue for a different level.

The best argument that they are too high is more specific. The downside keeps a 14.0% return on new capital in its terminal year, well below what the business has earned but still above the 9.91% cost of capital, so it stops short of a collapse in returns. Two antitrust suits besides the class action settlement awaiting approval remain open, and the company cannot estimate their cost. The blended instruments revenue per procedure we apply to Ion, whose share of procedures rises from about 5% to about 8% in our forecast, is probably too high if Ion carries lower revenue per procedure, and the company does not report it; a hypothetical stress at half the blended figure takes a few dollars off the reference. And the fourth quarter implies revenue growth of 16.6% in our reference against 21.0% for the first nine months, a slowdown we produce by holding procedure growth to guidance and applying no other change; if the quarter grew as fast as the year so far, the reference would be $195.36 rather than $193.46. We chose to leave that conservatism visible.

We find neither case strong enough to move the price toward our values or our values toward the price. The market's own price is the main outside observation we have, and agreement with it would be no proof while disagreement is not a defect. We have no approved Street estimate to compare, so our outside view is structural and we say so.

The items to watch are the fourth-quarter results, which include the first China price changes and whose date we have not seen confirmed in anything we captured; the pricing for extended-use and volume-based instruments in the first half of 2027, as the company describes its plan; court approval of the settlement, for which no date appears in the filings we read; and the US growth rate, where the question is whether it stabilizes or keeps falling.